Krossa S, Andersen MK, Sandholm EM, Wess M, Kiviaho A, Sharma A, Hakkola S, Hao Y, Alshalalfa M, Davicioni E, Viset T, Størkersen Ø, Karnes RJ, Spratt DE, Giskeødegård GF, Nykter M, Rye MB, Urbanucci A, Tessem MB (2025)
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment
Nat Commun, 16 (1), 10160
DOI 10.1038/s41467-025-65161-9, PubMed 41258098

Grist E, Dutey-Magni P, Parry MA, Mendes L, Sachdeva A, Proudfoot JA, Hamid AA, Ismail M, Howlett S, Friedrich S, DePaula Oliveira L, Murphy L, Brawley C, Dairo O, Lall S, Liu Y, Wetterskog D, Wingate A, Nowakowska K, Zakka L, Amos CL, Atako NB, Wang V, Rush HL, Jones RJ et al. (2025)
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Cell, 188 (20), 5717-5734.e10
DOI 10.1016/j.cell.2025.07.042, PubMed 40865526

Liukaityte R, Stenberg VY, Kleinauskas A, Juzenas P, Urbanucci A, Juzeniene A (2025)
Combination of PSMA targeting alpha-emitting radioligand [²¹²Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models
Med Oncol, 42 (8), 362
DOI 10.1007/s12032-025-02925-9, PubMed 40694184